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Abstract
Native Factor V is an anticoagulant, but when activated by thrombin, Factor X or platelet proteases,
it becomes a procoagulant. Due to these double properties, Factor V plays a crucial role in the
regulation of coagulation/anticoagulation balance.
Factor V Leiden (FVL) disorder may lead to thrombophilia. Whether a reduction in the activation
of Factor V or Factor V Leiden may correct the disposition to thrombophilia is unknown.
Therefore we tested SV-IV Peptide 1–16 (i.e. a peptide derived by seminal protein vescicle number
IV, SV-IV) to assess its capacity to inhibit the procoagulant activity of normal clotting factor V or
Factor V Leiden (FVL). We found that SV-IV protein has potent anti-inflammatory and
immunomodulatory properties and also exerts procoagulant activity. In the present work we show
that the SV-IV Peptide 1–16, incubated with plasma containing normal Factor V or FVL plasma for
5 minutes reduces the procoagulant capacity of both substances. This is an anticoagulant effect
whereas SV-IV protein is a procoagulant. This activity is effective both in terms of the coagulation
tests, where coagulation times are increased, and in terms of biochemical tests conducted with
purified molecules, where Factor X activation is reduced.
Peptide 1–16 was, in the pure molecule system, first incubated for 5 minutes with purified Factor
V then it was added to the mix of phosphatidylserine, Ca2+, Factor X and its chromogenic molecule
Chromozym X. We observed a more than 50% reduction in lysis of chromogenic molecule
Chromozym X by Factor Xa, compared to the sample without Peptide 1–16. Such reduction in
Chromozym X lysis, is explained with the reduced activation of Factor X by partial inactivation of
Factor V by Peptide 1–16. Thus our study demonstrates that Peptide 1–16 reduces the coagulation
capacity of Factor V and Factor V Leiden in vitro, and, in turn, causes factor X reduced activation.
Introduction
We have recently studied the Protein SV-IV (Seminal vesi-
cle protein number IV) [1-3]. According to its mobility in
SDS/PAGE, SV-IV protein is a basic, thermostable, secre-
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tory protein of low molecular weight (9758 d) and it is
synthesized by the epithelium of a rat seminal vesicle (SV)
under strict androgen transcriptional control [1-4]. SV-IV
immunorelated proteins have been found in several rat
tissues (uterus, lung, liver, brain and so on), and in
human seminal fluid secretion. The amino acids sequence
of Protein SV-IV is 90 amino-acids long and is encoded by
a gene that has been identified, sequenced and expressed
in Escherichia coli [5-9].
We found that SV-IV Protein has potent anti-inflamma-
tory and immunomodulatory properties and also exerts
procoagulant activity [4,10-15]. We sought to find a corre-
lation between a function of the molecule and its structure
and to assess if portions of the protein, fragments or pep-
tides, individually tested, would reveal one or more of the
molecule's reported functions [4,10-15]. We already
showed that the fragment 1–70 of SV-IV is responsible for
the procoagulant function of the molecule [14-18]. We
decided to study a small segments of such fragment 1–70
in order to assess which sequence was specifically respon-
sible of its activity [4,17]. We synthesised small peptides
such as SV-IV Peptide 1–8, Peptide 8–16 and Peptide 1–
16 of the fragment 1–70 [4].
Factor V is synthesized by megacaryocites, endothelial
cells and hepatocytes. Native Factor V is an anticoagulant,
but when activated by thrombin, Factor X or platelet pro-
teases, it becomes a procoagulant. Physiologically, it can
be activated by Factor X activated (Xa) and platelet pro-
teases but usually it is largely activated by thrombin, so
Factor V becomes Factor V activated (Va) [19]. It is a large
protein with a molecular weight of 300.000 d. Factor V
binds the phospholipids of cellular membranes, such as
platelets, endothelial cells, and monocytes, in the pres-
ence of calcium, and forms a receptor for Factor X and Pro-
thrombin [20,21]. This last complex, named
Prothrombinase, is responsible for cleaving prothrombin
to form thrombin. This complex is much more efficient
than Factor Xa alone in the prothrombin conversion. The
native (i.e. inactivated) Factor V, however, is an anticoag-
ulant. Native Factor V and Protein S are synergistic co-fac-
tors in the anticoagulant-inhibitory action of the activated
Protein C [19,21], which inhibits coagulation by breaking
down Factor Va (i.e. after its activation) and Factor VIIIa
thus leading to a slow thrombin generation.
When activated, Factor V loses this anticoagulant property
[19]. Consequently, due to its double properties in its
native and activated forms, Factor V plays a relevant role
in coagulation/anticoagulation balance [4,19]. Should
Factor V anticoagulant capacity be utilised, it would be
sufficient to inhibit or reduce the activation of Factor V.
Factor V Leiden (FVL) is a gene variant of clotting Factor V
and it is responsible for the major forms of activated Pro-
tein C resistance. The structural difference of normal Fac-
tor V compared to Factor V Leiden consists in a
substitution of an Arg with Gln in position 506, that is
responsible for FVL absent lysis by the activated Protein C,
but as far as factor X activation is concerned they are com-
parable [19-21]. The absent lysis in FVL causes throm-
bophilia by activating Factor X, therefore leading to an
increase of the procoagulant potency, because normal
Factor V is joined with FVL, that has not been broken
down by activated Protein C. Therefore, we tried to reduce
the procoagulant activity of normal Factor Va and also of
FVL activated by Peptide1–16. Then, we also evaluated the
activities of Peptide1–16 incubated with plasma contain-
ing normal Factor V or FVL in diversified coagulation sys-
tems in vitro and\or incubated with Factor V in a system
of pure molecules.
Methods
INBIOS Company, via Olivetti 1, Pozzuoli, Naples, Italy
provided the organic synthesis on solid phase of SV-IV
Peptide 1–16, since now is well known amino acid
sequence of Protein SV-IV. The amino acids sequence is
RKTKEKYSQSEEVVSE. The Thrombosis Center of the Isti-
tuto Clinico Humanitas, via Manzoni 56, Rozzano, Milan,
Italy and the Department of Internal Medicine of the
Buon Consiglio Fatebenefratelli Hospital of Naples pro-
vided plasma samples taken from twelve patients carriers
of FVL.
Selected patients carriers of FVL were affected by previous
thrombotic disease except 2 subjects that had not experi-
enced any thrombotic manifestation in their anamnesis
and that have been monitored for a couple of years.
Blood samples were obtained by venipuncture from
antecubital vein and collected in sodium citrate 0.11 M
tubes in 9:1 v\v in three aliquots of 5 mL and also in EDTA
in one aliquot of 5 mL from all subjects.
All samples were tested to confirm the presence of FVL in
order to confirm the thrombophilic state. The presence of
FVL was confirmed with DNA extraction from the sample
in EDTA and using the "NUCLEON BACC" kit (Amer-
shan, Germany); Factor V G1691A gene polymorphism
(i.e. FVL) was researched using PCR amplification with
specific primers and the Light Cycler apparatus (Roche,
Milan, Italy). Behring Institute (Protein C reagent, Dade
Bhering, Milan, Italy) provided the kit to assess resistance
to activated Protein C, which is altered in carrier of FVL as
it contains Agkistrodom Contortix venom as the Protein C
activator.Journal of Translational Medicine 2007, 5:69 http://www.translational-medicine.com/content/5/1/69
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The activated partial thromboplastin time (aPTT) reagent
(Ellagic acid and phospholipids) necessary for aPTT tech-
nique was also provided by Bhering Institute (Thrombo-
plastin time, Milan, Italy).
Sigma, Milan, Italy, provided Factor V deficient plasmas,
purified Factor V, purified Factor X, Phosphatidylserine
and Chromozym X (Human Factor V deficient plasma,
Sigma, Milan, Italy; Human Plasma Factor V, Sigma,
Milan, Italy; Human Plasma Factor X, Sigma, Milan, Italy;
Phosphatidylserine, Sigma, Milan, Italy; Chromozyn X,
Sigma, Milan, Italy, respectively).
Once obtained all materials we developed study tech-
niques to assess possible interference of Peptide 1–16
with Factor V and Factor V Leiden. We had to prove before
the factor V activation to factor Va: in pure molecules fac-
tor V, phosphatidylserine, Ca2+ and factor X system, we
attempted to obtain factor X activation to factor Xa by fac-
tor V activation to Va; we have varied the physiological
concentrations, increasing some component concentra-
tion of the system: phosphatidylserine, not phospholipid
complex, and factor X increased concentration, because
we have further coactivators lacking in vitro. After testing
the 50 or 5 or 1 µM peptide1–16 concentractions both
with plasmas and pure molecules we noted that 1 mM not
produced variation whereas 50 and 5 µM produced same
variations and both the concentrations required the incu-
bation time of 5 minutes. Here we report the reagents
used to perform the in vitro's experiences.
1) NaCl solution: 0,15 M
2) CaCl2 solution: 25 mM
3) aPTT reagent (phospholipids plus ellagic acid from the
kit)
4) Peptide 1–16 solution: 50 µM
5) Factor V solution: 16,6 µM; concentration in tests 0,166
µM
6) Factor X solution: 61 µM;
7) Phosphatidylserine solution: 12,5 µg/µL
8) solution of Chromozym X substrate: 1,9 mM.
Experimental tests were performed by several study tech-
niques:
 coagulative technique
 biochemical technique (conducted with purified mole-
cules)
Coagulation techniques included the aPTT test technique,
performed using factor V deficient plasma and purified
Factor V; moreover a further coagulation technique was
performed with Leiden plasmas compared to normal plas-
mas when incubated with Peptide 1–16 or NaCl as con-
trol.
A volume of 50 µl of aPTT reagent's was added to 100 µl
of Factor V deficient plasmas and was incubated at 37°C
for 1 minute and then 10 µl of purified Factor V incubated
with 7 µl of Peptide 1–16 or 7 µl of NaCl for 5 minutes;
then 100 µl CaCl2 was added and the coagulation time
was recorded.
Coagulation techniques were also performed with Leiden
plasma incubated for 5 minutes with Peptide 1–16 or
NaCl; to 100 µl Leiden plasma plus 7 µl Peptide1–16 or
NaCl incubated for 5 minutes was added 50 mcl aPTT rea-
gent and, after incubation for 1 minutes, was furtherly
added 100 µl CaCl2; then the coagulation time was regis-
tered. Thereafter the same procedure were performed with
normal plasma: we incubated normal plasma for 5 min-
utes with Peptide 1–16 or NaCl; to 100 µl normal plasma
plus 7 µl Peptide 1–16 or NaCl incubated for 5 minutes
was added 50 µl aPTT reagent and after 1 minute, we
added 100 µl of CaCl2, then the coagulation time was reg-
istered again. We chose to incubate the peptide 1–16 with
purified factor V or normal or Leiden plasma for 5 min-
utes because the incubation for 5 or 7 or 9 minutes gave
the same results in previous experiences (data not
shown). Five tests were conducted on each plasma sample
and the result was given as media with SD for all per-
formed tests.
Biochemical techniques with pure molecules aimed to
carry out Factor X activation by Factor Va. For Factor X
activation, Factor V and FVL operate in the same way.
Once activated, Factor X breaks down its chromogenic
substrate Chromozym X. The scission of the Chromozym
X produces a coloured molecule and its concentration and
colour depended directly on the concentration of acti-
vated Factor X. The activation of Factor V to Va, that
actives Factor X has been obtained with incubation of
phosphatidylserine and Ca2+, and then added to Factor X.
The final concentrations of used molecules are shown
below:
10 µl Phosphatidylserine (100 ng) and 10 µl of purified
Factor V (0,02 µM) and CaCl2, then incubated at 37°C for
3 minutes. Then the process was: 10 µl Phosphatidylser-
ine added to 10 µl of purified Factor V added to CaCl2

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added to 20 µl of purified Factor X (12,2 µM) and incu-
bated at 37°C for 3 minutes. Thereafter, a volume of
1,120 µl NaCl (0,15 mM) was added to 20 µl of Chro-
mozym X. OD readings were taken at 405 nm after 15
minutes in order to know the Chromozym X lysis.
Obtained values were recorded as control value of Chro-
mozym X lysis.
We substitute Peptide 1–16 to NaCl and we tested the
incubation of the mixture of purified Factor V with Pep-
tide 1–16 for 5 minutes; this mix was then added to the
phosphatidylserine, CaCl2 and factor X mixture and incu-
bated for 3 minutes. Then, Chromozym X was added and
OD readings were taken at 405 nm after 15 minutes incu-
bation. Obtained values were recorded as results of the
inhibiting clotting activities of peptide 1–16 against puri-
fied factor V.
Five tests were conducted on each samples. Result repre-
sent the media with SD of all performed tests.
Statistical analysis
Statistical analysis was based on the one way analysis of
variance (ANOVA); differences were considered to be sig-
nificant if p was < 0.05. Statistical analysis were carried out
using SPSS statistical software.
Results
The coagulation time of aPTT test of normal plasmas and
plasmas containing FVL and aPTT reagent plus NaCl and
CaCl2 was normal and no differences were found
between normal plasmas and Leiden plasmas: 36 +\- 3
seconds and 37 +/- 2 seconds respectively (data not
shown). No differences were found between aPTT of nor-
mal plasmas and Leiden plasmas at time T0, when we per-
formed the incubation with peptide 1–16 or NaCl
(respectively 40 +/- 5 seconds and 38 +/- 3 seconds); when
we incubated the Peptide 1–16 with normal or Leiden
plasmas for 5 minutes, the coagulation time turned
respectively to 96 +/- 6 seconds and 100 +\- 5 seconds
reaching statistical significance (96 +/- 6 seconds versus
38 +/- 3 seconds, p: < 0.001, s; and 100 +/- 5 seconds ver-
sus 38 +/- 5 seconds, p: 0.001, s) (Table 1).
Moreover, the coagulation time was also obtained by the
aPTT test with deficient Factor V plasma and purified Fac-
tor V incubated with NaCl or Peptide 1–16 for 5 minutes
plus aPTT reagent (Ellagic acid and phospholipids) and
CaCl2. When we incubated NaCl, the coagulation time
was normal: 35 +\- 4 seconds and 39 +/- 4 seconds respec-
tively; when the Peptide 1–16 substituted NaCl, the coag-
ulation time was significantly longer: 96 +\- 7 seconds, p:
< 0.001 (Table 2).
As control of previous experiments, in the biochemical
tests, purified Factor V activation was obtained by the
incubation for 3 minutes with phosphatidilserine, CaCl2,
in presence of factor X with Chromozym X, and NaCl (as
control of next tests) in order to activate Factor X with
pure molecules: the Factor X incubated for 3 minutes and
Chromozym X, incubated for 15 minutes. We obtained a
coloured product with an optical density (O.D.) of 0.420
nm. On the other hand, when we incubated Factor V with
Peptide1–16 (instead of NaCl) for 5 minutes and then
added to the mixture of phospatidilserine and CaCl2 with
subsequent addition of factor X and Chromozym X, we
obtained a significantly different optical density (O.D.) of
0.190 nm, p: < 0.0001, s (Table 3).
Discussion
Whether factor V has sufficient endogenic activity to allow
small amount factor Xa generation is still a matter of
debate [22]. Data from literature report that factor V circu-
lates as a single chain protein with about 0.27% of prote-
olitic activity comparable to Va [23]. Foster et al.[24]
postulate that factor V appears to be a procofactor with 1/
Table 1: aPTT coagulation time of normal plasma and Leiden plasma (100 µL) with and without incubation for 5 minutes with peptide 
1–16 or NaCl as control.
Plasmas incubated with 
peptide 1–16
aPTT coagulation 
time (sec.)
Plasmas incubated 
with NaCl
aPTT coagulation 
time (sec.)
p
Normal plasma incubated at T0 
with peptide 1–16
40 ± 5 Normal plasma incubated at 
T0 with NaCl
38 ± 3 0,16
Leiden plasma incubated at T0 with 
peptide 1–16
41 ± 4 Leiden plasma incubated at 
T0 with NaCl
40 ± 4 0,59
Normal plasma incubated with 
peptide 1–16 at T1
90 ± 6 Normal plasma incubated at 
T1 with NaCl
37 ± 4 0,000
Leiden plasma incubated at T1 with 
peptide 1–16
120 ± 9 Leiden plasma incubated at 
T1 with NaCl
38 ± 3 0,000
aPTT: activated partial thromboplastin time
sec.: seconds
T0: time of incubation
T1: 5 minutes after the incubation
NaCl: sodium clorureJournal of Translational Medicine 2007, 5:69 http://www.translational-medicine.com/content/5/1/69
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400 the activity of full activated factor V (i.e. factor Va).
The proteolytic conversion of factor V to factor Va is cata-
lysed by thrombin and Xa. However, because factor Va is
required for thrombin generation, the initial participation
of factor V in the expression of prothrombinase activity is
not well understood [24]. Orfeo et al. demonstrated [25]
that prothrombinase complex consists of the protease fac-
tor Xa, Ca2 and factor V assembled on phospholipid
membrane. Factor Va functions both as a receptor for fac-
tor Xa and as a positive effector for factor Xa catalytic effi-
ciency, thus being a key factor for an efficient conversion
of prothrombin to thrombin. The activation of the proco-
factor factor V to factor Va is an essential reaction that
occurs early in the process of tissue factor pathway, how-
ever the catalytic sequence leading to formation of factor
Va is still a controversial issue [25]. We attempted, by a
system consisting of pure molecules (i.e. factor V, phos-
phatidylserine, Ca2 and factor X) to obtain factor X activa-
tion to Xa through factor V activation to factor Va. We
varied the physiological concentrations, increasing the
same components of the system and chose to work only
with phosphatidylserine and not phospholipid complex
and to increase factor X concentration. This system pro-
duced factor X activation to Xa. We tested factor Xa pepti-
dolytic activity with Chromozym X, that is a specific
chromogenic molecule of factor Xa; when we added Chro-
mozym X to this system, it generated colour, indicating
that factor X in our system became Xa. Then, we incubated
purified factor V with Peptide 1–16 for 5 minutes, and
thereafter we added it to the same mixture, in order to
prove if this Peptide 1–16 hampers factor V activation. In
this system, in fact, factor X activation is reduced, as dem-
onstrated by reduced lysis of chromozym X.
FVL is an inherited condition leading to thrombophilia
through the activated protein C resistance. In presence of
FVL, the activated Protein C does not breakdown FVL, that
accumulates so increasing the global coagulative power in
the coagulative cascade and impairing the coagula-
tion\anticoagulation balance. The results of our experi-
ments demonstrate clearly that Peptide1–16 inhibits the
activity both of FVL and of normal clotting factor V, in
particular its ability to activate Factor X. We demonstrated
that the Leiden Plasmas incubated with the Peptide 1–16
cause an increase in the coagulation time in the test of
aPTT, as reported in Table 1.
Data obtained by incubating Peptide 1–16 with purified
Factor V for 5 minutes, then added to factor V deficient
plasma, confirmed such results. In fact when we added
this mixture to deficient Factor V Plasmas in an aPTT test
we found a prolonged coagulation time compared to con-
trol (i.e. with NaCl without peptide 1–16), as reported in
Table 2.
Moreover, considering that in the Factor X activation, Fac-
tor V and FVL operate in the same way, to verify Factor X
activation, we only tested the ability of purified Factor V
activated by pure molecules as phosphatidilserine and
CaCl2. Then we added this mixture to Factor X and Chro-
mozym X, in order to cause the lysis of Chromozym X by
Xa: we obtained an optical density of 0.420 nm which
clearly demonstrates the lysis of Chromozym X. Yet, if we
incubate for 5 minutes Factor V and Peptide 1–16 and we
add them to the mixture of pure molecules (phosphatidil-
serine and CaCl2) and thereafter to Factor X and Chro-
mozym X, we observed that Factor X activation caused a
Table 2: aPTT coagulation time of deficient factor V plasma added to purified factor V (100 µL) and incubated with peptide 1–16 or 
NaCl as control.
Test aPTT coagulation 
time (sec.)
Test aPTT coagulation 
time (sec.)
p
Deficient factor V plasma 
added to purified factor V 
and NaCl
36 ± 4 Deficient factor V plasma 
added to purified and 
peptide 1–16
119 ± 7 0,000
aPTT: activated partial thromboplastin time
sec.: seconds
NaCl: sodium clorure
Table 3: Factor X activation test (O.D.): purified factor V (0.002 µM) incubated with peptide 1–16 or NaCl for 5 minutes and thereafter 
added to phosphatidilserine and CaCl2 and factor X and Chromozyn X for 15 minutes.
Parameter Mixture with NaCl Mixture with peptide 1–16 p
O.D. (nm) of Chromozyn X 0.420 ± 0.008 0.190 ± 0.006 0,000
O.D.: optical density
nm: nanometers
CaCl2: calcium clorure
NaCl: sodium clorureJournal of Translational Medicine 2007, 5:69 http://www.translational-medicine.com/content/5/1/69
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reduced lysis of Chromozym at an optical density of 0,190
nm. Therefore, Factor X activation is significantly slower
compared to control (i.e. NaCl and purified Factor V), and
this is confirmed by a reduced lysis of Chromozym X (i.e.
O.D. = 0.190).
The occurring contact of the two molecules, Factor V and
Peptide1–16, is proved by the fact that both incubated at
time 0 and added to phosphatidylserine and CaCl2 pro-
duced a different effect compared to that obtained if we
incubate Factor V, alone for 5 minutes, without Peptide 1–
16. This suggests that the observed events were caused by
the incubation of the two molecules and that 5 minutes
are needed for their effective interaction. Our results indi-
cate that Peptide 1–16 is not only an inhibitor of normal
clotting factor V but also of FVL. So, Peptide 1–16 may
represent an inhibitor of clotting cascade also in presence
of inherited thrombophilic disorder leading to hypercoag-
ulable state as FVL. We demonstrated, in fact, the inhibi-
tion of clotting cascade in presence of normal factor V and
also in the presence of plasmas containing FVL by both
coagulation techniques and\or biochemical approaches.
One may argue that in our studies we used purified factor
V to test the normal cascade and FVL from plasma of sub-
jects carrying this kind of alteration. However we point
out that in biochemical tests, normal purified factor V
alone was incubated with Peptide 1–16 while purified
FVL was not incubated with Peptide 1–16 because puri-
fied FVL is not available commercially both for experi-
mental studies and\or clinical approaches. Moreover it is
really difficult to obtain purified FVL from plasma of sub-
jects carrying this alteration. Yet, the presence of purified
FVL is not necessary for our studies because the role of
normal Factor V and Factor V Leiden in Factor X activation
is comparable.
In conclusion, our study demonstrates that Peptide1–16
may represent a specific antagonist of FVL and one may
envision its use in the thrombophilic FVL patients, should
further studies confirm our results.
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